CY1108963T1 - Λιπαρα οξεα μεσης-αλυσου, γλυκεριδια και αναλογα ως διεγερτες ερυθροποιησης - Google Patents

Λιπαρα οξεα μεσης-αλυσου, γλυκεριδια και αναλογα ως διεγερτες ερυθροποιησης

Info

Publication number
CY1108963T1
CY1108963T1 CY20091100397T CY091100397T CY1108963T1 CY 1108963 T1 CY1108963 T1 CY 1108963T1 CY 20091100397 T CY20091100397 T CY 20091100397T CY 091100397 T CY091100397 T CY 091100397T CY 1108963 T1 CY1108963 T1 CY 1108963T1
Authority
CY
Cyprus
Prior art keywords
glycerides
analogs
oil fat
chain oil
fat acids
Prior art date
Application number
CY20091100397T
Other languages
English (en)
Inventor
Christopher Penney
Lyne Gagnon
Pierre Laurin
Boulos Zacharie
Original Assignee
Prometic Biosciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc. filed Critical Prometic Biosciences Inc.
Publication of CY1108963T1 publication Critical patent/CY1108963T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Χρήση μιας σύνθεσης που περιλαμβάνει μια ένωση οποιουδήποτε των τύπων I, II, IIa, III και IIIa ή συνδυασμό αυτών, όπου έκαστο R1 ανεξαρτήτως είναι C7-11 αλκύλ, τα Α και Β ανεξαρτήτως είναι Η ή CO R1, το R2 είναι Η ή C1-4 αλκύλ, το Μ είναι μονοκατιόν μετάλλου (k = 1) ή δικατιόν (k = 2), το Υ είναι Ο ή ΝΗ και το Ζ είναι Ο, ΝΗ, CH2O ή ένας δεσμός για τη βιομηχανική κατασκευή ενός φαρμάκου για διέγερση ερυθροποίησης. Κατά προτίμηση, η σύνθεση περαιτέρω περιλαμβάνει ανθρώπινη ερυθροποιητίνη.
CY20091100397T 2003-02-07 2009-04-06 Λιπαρα οξεα μεσης-αλυσου, γλυκεριδια και αναλογα ως διεγερτες ερυθροποιησης CY1108963T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44545403P 2003-02-07 2003-02-07
EP04708802A EP1592416B1 (en) 2003-02-07 2004-02-06 Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis

Publications (1)

Publication Number Publication Date
CY1108963T1 true CY1108963T1 (el) 2014-07-02

Family

ID=32850990

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100397T CY1108963T1 (el) 2003-02-07 2009-04-06 Λιπαρα οξεα μεσης-αλυσου, γλυκεριδια και αναλογα ως διεγερτες ερυθροποιησης

Country Status (28)

Country Link
US (1) US9682054B2 (el)
EP (1) EP1592416B1 (el)
JP (1) JP5390070B2 (el)
KR (1) KR101120775B1 (el)
CN (1) CN100427081C (el)
AP (1) AP2005003367A0 (el)
AR (1) AR043120A1 (el)
AT (1) ATE419846T1 (el)
AU (1) AU2004210193B2 (el)
BR (1) BRPI0407276A (el)
CA (1) CA2515160C (el)
CY (1) CY1108963T1 (el)
DE (2) DE602004018902D1 (el)
DK (1) DK1592416T3 (el)
EA (1) EA009939B1 (el)
ES (1) ES2255467T3 (el)
IL (1) IL170057A (el)
JO (1) JO2705B1 (el)
MA (1) MA27664A1 (el)
MX (1) MXPA05008382A (el)
MY (1) MY140913A (el)
NO (1) NO334085B1 (el)
NZ (1) NZ541593A (el)
PT (1) PT1592416E (el)
SI (1) SI1592416T1 (el)
TN (1) TNSN05189A1 (el)
WO (1) WO2004069237A1 (el)
ZA (1) ZA200506246B (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5026655B2 (ja) 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
MXPA06011871A (es) * 2004-04-15 2007-10-08 Chiasma Inc Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
EP2332977B1 (en) 2004-07-23 2015-11-25 Acceleron Pharma Inc. ActRII receptor polypeptides
EA200700543A1 (ru) * 2004-09-03 2007-10-26 Прометик Байосайенсиз Инк. Замещенные пуринилпроизводные с иммуномодулирующей и химиозащитной активностью и их применение как таковых или с жирными кислотами со средней длиной цепи или глицеридами
JP4948414B2 (ja) * 2004-10-01 2012-06-06 プロメティック バイオサイエンシズ インコーポレーテッド 造血刺激剤としての中間鎖長脂肪アルコール
US8071580B2 (en) * 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
DK1973559T3 (da) 2005-11-23 2013-03-25 Acceleron Pharma Inc Activin-ActRIIa antagonister samt anvendelser til fremme af knoglevækst
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN103920139B (zh) 2007-02-01 2018-02-02 阿塞勒隆制药公司 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI459963B (zh) 2007-02-09 2014-11-11 Acceleron Pharma Inc 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
EP2299998B1 (en) * 2007-11-02 2018-01-03 Prometic Pharma Smt Limited Medium-chain length fatty acids and glycerides as nephroprotection agents
NZ586249A (en) * 2007-12-19 2012-05-25 Prometic Biosciences Inc A combination of medium-chain length fatty acids, salts or triglycerides, gemcitabine, and optionally erlotinib, for the treatment of pancreatic cancer
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010032140A2 (en) 2008-09-17 2010-03-25 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
EP2440576A4 (en) 2009-06-08 2013-11-20 Acceleron Pharma Inc PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
KR20210034684A (ko) 2009-06-12 2021-03-30 악셀레론 파마 인코포레이티드 절두된 ActRIIB-FC 융합 단백질
EP3838919A1 (en) * 2009-08-13 2021-06-23 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ, インコーポレイテッド Actriia結合剤およびその使用
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Smt有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
KR102279522B1 (ko) 2012-11-02 2021-07-19 셀진 코포레이션 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
CN102973922B (zh) * 2012-12-18 2016-02-03 华东理工大学 一种融合蛋白的应用
EP3154566B1 (en) 2014-06-13 2022-08-03 Acceleron Pharma Inc. Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
HUE062189T2 (hu) 2014-12-03 2023-09-28 Celgene Corp Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére
MA41462A (fr) 2015-02-03 2021-05-12 Chiasma Inc Méthode de traitement de maladies
US20170021029A1 (en) * 2015-04-15 2017-01-26 Jeffrey Charles Raber Topical formulations and uses
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871768A (en) 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US6060459A (en) 1987-10-28 2000-05-09 Pro-Neuron, Inc. Enhancing blood cell count with oxypurine nucleosides
US5011852A (en) 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JP3014119B2 (ja) * 1990-05-28 2000-02-28 雪印乳業株式会社 直腸投与用赤血球造血剤
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
ES2097783T3 (es) * 1991-01-15 1997-04-16 Hemosphere Inc Nanomatrices proteicas y procedimiento de produccion.
JPH05163160A (ja) 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5214035A (en) 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
WO1995030413A1 (fr) 1994-05-10 1995-11-16 The Kitasato Institute Accelerateur de proliferation de cellules souches hematopoietiques
US5470861A (en) 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
JPH08208510A (ja) 1994-11-03 1996-08-13 F Hoffmann La Roche Ag インターフェロン組成物
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
AUPN933396A0 (en) 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (ja) 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
JP2001514209A (ja) * 1997-09-04 2001-09-11 バイオゾーン ラボラトリーズ,インコーポレイテッド 経口リポソーム送達系
IL135989A0 (en) * 1997-11-14 2001-05-20 Skyepharma Inc Processes for the production of multivesicular liposomes
BR9814693B1 (pt) 1997-11-19 2011-04-19 suspensões de polìmero fluidificado de polissacarìdeos catiÈnicos em emolientes e processo para preparação de uma composição para cuidado pessoal.
WO1999026640A1 (en) 1997-11-20 1999-06-03 Bukwang Pharm. Ind. Co., Ltd. Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes
ES2224299T3 (es) * 1998-02-23 2005-03-01 Cilag Ag International Dispersion liposomal de eritroyetina.
DE69910183T2 (de) 1998-03-11 2004-06-03 Grelan Pharmaceutical Co., Ltd., Hamura Darmlösliche sprudelnde zusammensetzungen
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
CA2385989A1 (en) 1999-09-27 2001-04-05 Andrew Nienstedt Compositions of tocol-soluble therapeutics
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
DE60123603T2 (de) 2000-06-14 2007-08-16 William Leslie Diss Porter Lipide zur änderung des abwehrsystems
US6967028B2 (en) 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
JP5026655B2 (ja) 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
US20040052836A1 (en) 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
US6725510B1 (en) 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
KR101120813B1 (ko) 2003-07-25 2012-03-23 프로메틱 바이오사이언시즈 인코포레이티드 중-쇄 지방산 금속염의 제조 방법
EA200700543A1 (ru) 2004-09-03 2007-10-26 Прометик Байосайенсиз Инк. Замещенные пуринилпроизводные с иммуномодулирующей и химиозащитной активностью и их применение как таковых или с жирными кислотами со средней длиной цепи или глицеридами
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Also Published As

Publication number Publication date
CN1753665A (zh) 2006-03-29
CN100427081C (zh) 2008-10-22
ATE419846T1 (de) 2009-01-15
ZA200506246B (en) 2006-12-27
NO334085B1 (no) 2013-12-09
US9682054B2 (en) 2017-06-20
KR101120775B1 (ko) 2012-04-18
AU2004210193B2 (en) 2007-07-12
DE04708802T1 (de) 2006-06-22
ES2255467T3 (es) 2009-05-01
EP1592416B1 (en) 2009-01-07
MXPA05008382A (es) 2005-11-04
MY140913A (en) 2010-01-29
MA27664A1 (fr) 2005-12-01
JP2006516987A (ja) 2006-07-13
JO2705B1 (ar) 2014-03-15
EP1592416A1 (en) 2005-11-09
CA2515160C (en) 2013-01-08
JP5390070B2 (ja) 2014-01-15
DK1592416T3 (da) 2009-04-20
WO2004069237A1 (en) 2004-08-19
PT1592416E (pt) 2009-04-03
NZ541593A (en) 2009-05-31
NO20053994D0 (no) 2005-08-26
SI1592416T1 (sl) 2009-06-30
AR043120A1 (es) 2005-07-20
AP2005003367A0 (en) 2005-09-30
DE602004018902D1 (de) 2009-02-26
NO20053994L (no) 2005-10-06
IL170057A (en) 2011-09-27
AU2004210193A1 (en) 2004-08-19
BRPI0407276A (pt) 2006-01-31
US20060128800A1 (en) 2006-06-15
KR20050118671A (ko) 2005-12-19
TNSN05189A1 (en) 2007-06-11
EA009939B1 (ru) 2008-04-28
CA2515160A1 (en) 2004-08-19
EA200501267A1 (ru) 2006-02-24
ES2255467T1 (es) 2006-07-01

Similar Documents

Publication Publication Date Title
CY1108963T1 (el) Λιπαρα οξεα μεσης-αλυσου, γλυκεριδια και αναλογα ως διεγερτες ερυθροποιησης
AR025225A1 (es) Feniloxazolidinonas heterociclicas biciclicas sustituidas antibacterianas y composiciones farmacéuticas
DK0639577T3 (da) Phosphonooxymethyl- eller methylthiomethylestere af taxanderivater som antitumormidler
AR028948A1 (es) Compuestos novedosos
ES2190396T3 (es) Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PT94568A (pt) Quinazolinonas substituidas como antagonistas da angiotensina ii
AR013494A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
UY28572A1 (es) Compuestos novedosos
PA8592001A1 (es) Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos
ECSP066898A (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
CY1105811T1 (el) Ενωσεις ενισχυτη ταξολης
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
UY28848A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, y su empleo como medicamentos
ES2031876T3 (es) Un procedimiento para la preparacion de 5,6-dihidro-2-(fenil sustituido)-1,2,4,-triazin-3,5(2h,4h)-dionas.
SE0301446D0 (sv) New Compounds
CO5031250A1 (es) Compuesto farmaceutico
PA8576001A1 (es) "difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion , medicamentos que comprenden estos compuestos y su uso".
UY26465A1 (es) Compuestos y composiciones antipicornavirales, sus usos farmacéuticos, y materiales para su sintesis.
CO4600635A1 (es) Procedimientos e intermedios para preparar derivados de cromanol sustituidos
CY1106396T1 (el) Γραμμικες ή κυκλικες ουριες, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις οι οποιες τις πepιεχουν
AR028947A1 (es) Compuestos novedosos
UY26988A1 (es) Nuevas indolinonas sustituidas, su preparación y su utilización como medicamentos.